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Abstract
Purpose Neuroendocrine neoplasia (NEN) has been displaying an incremental trend along the last two decades. This
phenomenon is poorly understood, and little information is available on risk factor for neuroendocrine neoplasia devel-
opment. Aim of this work is to elucidate the role of potentially modifiable risk factors for pancreatic and pulmonary NEN.
Methods We conducted a case–control study on 184 patients with NEN (100 pancreas and 84 lung) and 248 controls. The
structured questionnaire included 84 queries on socio-demographic, behavioral, dietary and clinical information.
Results Increased risk was associated with history of cancer (“other tumor”, lung OR= 7.18; 95% CI: 2.55–20.20 and pancreas
OR= 5.88; 95% CI: 2.43–14.22; “family history of tumor”, lung OR= 2.66; 95% CI: 1.53–4.64 and pancreas OR= 1.94; 95%
CI: 1.19–3.17; “family history of lung tumor”, lung OR= 2.56; 95% CI: 1.05–6.24 and pancreas OR= 2.60; 95% CI:
1.13–5.95). Type 2 diabetes mellitus associated with an increased risk of pancreatic NEN (OR= 3.01; 95% CI: 1.15–7.89).
Conclusions Besides site-specific risk factors, there is a significant link between neuroendocrine neoplasia and cancer in
general, pointing to a shared cancer predisposition.
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Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous
group of neoplasms in different anatomical sites [1]. Most
of NENs occur in the small intestine and pancreas, fol-
lowed by lung and the respiratory system and by colon
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and rectum [2, 3]. The incidence of these tumors is usually
lower than 5/100,000 [4–7]. NENs typically have a long
survival that results in a prevalence rate of 48/100,000 [2].
The epidemiology of NENs is changing, since in recent
years there was an increased incidence only partially
explained by better diagnostic techniques [8]. Increased
trend have been shown in various populations and in
different anatomical sites for both low-grade and high-
grade NENs [9–13].
Several risk factors have been associated with the risk of
developing NENs. A systematic review and meta-analysis
published in 2016 indicates family history of cancer as the
main risk factor for NENs of the pancreas, rectum, stomach
and lung [14]. Other important risk factors referring to
individual’s behavior such as cigarette smoking and alcohol
drinking, mainly affected lung and pancreas (ibidem).
We conducted a case–control study in three Italian cen-
ters with the aim to elucidate the role of potentially mod-
ifiable risk factors for the most prevalent and aggressive
NENs, pancreatic and pulmonary.
Materials and methods
Participants and study design
The design was prospective case–control study. Study cases
were patients with NENs of the pancreas and of the lung.
Cases were enrolled in three different Italian hospitals:
Policlinico Agostino Gemelli (Rome), Ospedale San Luigi
Gonzaga (Orbassano) and Ospedale di Circolo (Varese).
Patients with pancreatic or lung NENs were included.
Details on tumor functionality were not collected. Cases
with multiple endocrine neoplasia (MEN) were excluded.
Controls were randomly recruited among healthy indivi-
duals admitted at the same hospital of the cases, in the same
period, for non-neoplastic conditions. Individuals with
severe neurological or psychiatric disorders were excluded.
Enrollment lasted from 2014 to 2017.
Cases and controls were interviewed by trained inter-
viewers using a questionnaire including information on
socio-demographic, behavioral, dietary, and clinical infor-
mation. The variables were: demographic features; tumor
history; smoke habit; alcohol consumption; diet; exercise
and lifestyle; medical history and gynecological/obstetric
data (for women), investigated with 83 specific queries in
Italian language. All queries to patients referred to the time
prior to the diagnosis of neuroendocrine neoplasia. The
questionnaire was validated by the local ethics committee
and adopted in each center. All the information was col-
lected at each participating center and shared with the
coordinating center at the Fondazione Policlinico
Universitario IRCCS-Università Cattolica del Sacro Cuore
where data were checked and corrected for inconsistencies.
Participation rate was calculated as the proportion of
respondents who completed the interview.
Variables definition
Tumor grade was defined according to the WHO classifi-
cation of 2017 and 2019 for pancreatic NEN [15, 16] and
WHO 2015 for lung NEN tumors [17]. Smoking and
alcohol including information on status (never, former,
current) and to the intensity (number of pack-years and
number of drinks per day) respectively. The definition of
smoking/alcohol drinking/status was as follows: partici-
pants who were smoking (or drinking) until one year before
the diagnosis for cases and interview for controls were
defined as current smokers (or drinkers); participants who
quitted smoking (or drinking) more than one year before the
diagnosis for cases and the interview for controls were
defined as former smokers (or drinkers). Diet was defined
using the current Italian dietary definition and the Medi-
terranean diet score [18–20]. Exercise and life-style items
were defined as published [21]. Participants body mass
index (BMI) was categorized according to the World Health
Organization cutoff points [22].
Statistical analysis
Descriptive statistics were used to describe the participant’s
characteristics. Comparison between the distribution of
selected variables between cases and controls was con-
ducted using Student t test or Mann–Whitney test for con-
tinuous variables and Chi-squared of Fisher exact test for
categorical variables, where appropriate. Adjusted Odds
Ratios (ORs) and the 95% Confidence Intervals (CI) for the
association between selected variables and the risk of lung
NEN and pancreatic NEN were estimated using a multi-
variable logistic regression model. The following terms
were included in the model as confounders: age, gender,
family history of cancer and smoking intensity. In order to
minimize the potential confounder due to the inclusion of
prevalent cases [23], a separate analysis was conducted
including only the incident cases, defined as the cases that
were interviewed within one year of being diagnosed with
NENs. Two sensitivity analysis were conducted as follows:
(1) an analysis was conducted including age-matched cases
and controls and (2) an analysis was conducted that was
limited to TC and AC cases. All tests were two-sided and a
p value less than 0.05 was considered statistically sig-
nificant. Statistical analysis was conducted using Stata
software (StataCorp. 2013. Stata Statistical Software: ver-
sion 13. College Station, TX: StataCorp LP).
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Ethic Committee approval
Subjects gave written informed consent to this study. The
study protocol was approved by the Ethic Committee of
Fondazione Policlinico Universitario A. Gemelli – Uni-
versità Cattolica del Sacro Cuore (N. 27229/13).
Results
Participation rate was 98% for all study participants. A total
of 184 cases and 248 controls were included in the study,
the majority of which were recruited in the center of Rome
(81.0% of the cases and 96.4% of the controls).
Table 1 shows the distribution of cases with pancreatic
NEN, lung NEN cancer and controls according to selected
variables. A total of 100 cases (54.3%) had pancreatic NEN.
The age distribution of controls was significantly younger
compared to both lung (p < 0.001) and pancreatic NEN (p <
0.001).
Figure 1 displays the distribution of the tumor grade
stratified by anatomical site. In patients with lung NEN, 61
(72.6%) had a well-differentiated neoplasm with low degree
of malignancy, while 23 (27.4%) had a poorly differentiated
neoplasms with a high degree of malignancy. Forty-four
patients (72.1%) were typical carcinoid (TC) and 17
(20.2%) were atypical carcinoid (AC); seven patients
(8.3%) were large cell neuroendocrine carcinomas
(LCNEC) and 16 (19.0%) were small cell neuroendocrine
carcinomas (SCLC). In patients with pancreatic NEN, 89
(89.0%) had a well-differentiated neoplasm while 11
(11.0%) had poorly differentiated neoplasms with a high
degree of malignancy. Fifty-height patients (58.0%) were
NET G1, 31 (31.0%) were NET G2 and 11 (11.0%) NEC.
No NET G3 was observed.
Patients with both lung and pancreatic NENs were hea-
vier than controls. Pancreatic NEN patients had a higher
BMI compared to controls (p= 0.033). Patients with lung
NEN were more likely to be former or current smokers
compared to both controls and to pancreatic NEN. Among
patients with pancreatic NEN only, the prevalence of dia-
betes 2 was significantly higher compared to controls (p=
0.002). Both patients with lung and pancreatic NENs
reported a significantly higher prevalence of family history
of tumor compared to controls (p < 0.001 and p= 0.001,
respectively). Both patients with lung and pancreatic NENs
reported a significantly higher prevalence of family history
of lung cancer compared to controls.
In Table 2 the Odds Ratios (ORs) and corresponding
95% Confidence Intervals (95% CI) of pancreatic and lung
NENs are reported. Increased age at diagnosis was sig-
nificantly associated with increased risk of lung and pan-
creatic NENs (OR= 1.03, 95% CI: 1.01–1.05 for both lung
and pancreatic NENs). Type 2 diabetes mellitus was asso-
ciated with an increased risk of pancreatic NEN (OR=
3.01; 95% CI: 1.15–7.89), while history of another tumor
other than NENs was associated with an increased risk of
both lung and pancreatic NENs (OR= 7.18; 95% CI:
2.55–20.20 and OR= 5.88; 95% CI: 2.43–14.22, respec-
tively). Family history of any tumor and of lung cancer was
associated with increased risk of both lung and pancreatic
NENs (OR= 2.66; 95% CI: 1.53–4.64 and OR= 2.56;
95% CI: 1.05–6.24 for lung NEN, respectively; OR= 1.94;
95% CI: 1.19–3.17 and OR= 2.60; 95% CI: 1.13–5.95 for
pancreatic NEN, respectively). Similar findings were
obtained by a separate analysis including only the incident
cases (Supplementary Table 1) and in two sensitivity ana-
lysis limited to the age-matched participants and to TC and
AC cases.
Discussion
This work contributed novel population-based, case–control
data on risk factors associating with neuroendocrine cancer.
So far only 11 studies provided similar data (for review see
[14, 24, 25]).
Several risk factors were associated with NEN. Among
these, the most relevant is the presence of a concurrent
tumor (“other tumor”) conferring a significant OR of 7.27
(95% CI 3.04–17.39). This finding well aligns with the two
other cancer-related risk factors (“family history of cancer”
and “family history of lung cancer”) here identified as
significant though with lower ORs (2.24, 95% CI 1.47–3.40
and 2,54 95% CI 1.2–5.3, respectively). Thus, this study
provides further evidence that “family history of cancer” is
a well-known risk factor for both lung and pancreas neu-
roendocrine neoplasia. In addition, our data suggest a sig-
nificant link between neuroendocrine neoplasia and cancer
in general, pointing to a cancer predisposition landscape.
Genes involved in familial susceptibility are well known for
both lung and pancreas NEN. Heritable syndromes asso-
ciating with NEN development include the multiple endo-
crine neoplasia type 1 syndrome and, less frequently, the
von Hippel-Lindau, the neurofibromatosis type 1, the
Cowden, the tuberous sclerosis and the Li-Fraumeni syn-
dromes [26, 27]. During the last three years also deep
sequencing data on solid cancer unveiled unexpected
germline gene aberrations in neuroendocrine neoplasia
(e.g., MUTYH, CHEK2, and BRCA2 genes in pancreas
NEN) [28, 29] together with a substantial absence of known
cancer drivers [30, 31].
Gene-wide association studies (GWAS) are however
lacking for patients with neuroendocrine cancer so that
more subtle genetic associations have not been elucidated.
Though MEN1 patients were not enrolled in this study, we
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Table 1 Distribution of selected covariates among cases and controls
Characteristics Controls Cases
n % Lung NEN Pancreatic NEN
n % p valuea n % p valueb p valuec
Total 248 100.0 84 45.7 100 54.3
Case type 0.580
Incident – – 57 67.9 – 45 45.0 –
Prevalent – – 14 16.7 – 14 14.0 –
Missing – – 13 15.5 – 41 41.0 –
Age (years) <0.001 <0.001 0.274
≤45 106 42.7 18 21.4 18 18.0
46–60 67 27.0 21 25.0 36 36.0
>60 75 30.2 45 53.6 46 46.0
Missing 0 – 0 – 0 –
Gender 0.034 0.331 0.306
Male 100 40.3 45 53.6 46 46.0
Female 148 59.7 39 46.4 54 54.0
Missing 0 – 0 – 0 –
Heightd 167.3d 10.8d 169.2d 7.5d 0.121 168d 7.9d 0.774 0.157
Weightd 70.4d 14.8d 75.0d 14.5d 0.013 75.8d 14.7d 0.002 0.738
BMI 0.327 0.033 0.589
Underweight 12 4.8 3 3.6 3 3.0
Normal weight 69 27.8 21 25.0 17 17.0
Overweight 135 54.4 43 51.2 58 58.0
Obese 30 12.1 17 20.2 22 22.0
Missing 2 0.8 0 – 0 –
Education level 0.089 0.159 0.702
Low 80 32.3 38 45.2 42 42.0
Medium 98 39.5 31 36.9 35 35.0
High 58 23.4 14 16.7 22 22.0
Missing 12 4.8 1 1.2 1 1.0
Smoking status 0.028 0.120 0.002
Never 122 49.2 28 33.3 59 59.0
Former 75 30.2 37 44.0 29 29.0
Current 51 20.6 19 22.6 12 12.0
Missing 0 – 0 – 0 –
Smoking intensity <0.001 0.255 <0.001
Never 122 49.2 28 33.3 59 59.0
≤15 pack-years 66 26.6 17 20.2 23 23.0
>15 pack-years 56 22.6 38 45.2 17 17.0
Missing 4 1.6 1 1.2 1 1.0
Alcohol status 0.464 0.301 0.460
Never 127 51.2 37 44.0 51 51.0
Former 10 4.0 5 6.0 8 8.0
Current 111 44.8 42 50.0 41 41.0
Missing 0 – 0 – 0 –
Endocrine
may not exclude the presence of other hidden genetic trait(s)
in our cohort. Our results, however, may well represent an
epiphenomenon of ageing.
Our data confirm the two major risk factors (“type 2
diabetes” and “family history of cancer”) previously
reported for pancreas NEN [14, 24, 25]. Of note, since our
data referred to the time prior to the NEN diagnosis, the
potential influence of the tumor functionality or its therapy
on type 2 diabetes development is excluded. In addition, we
found the risk factors “other tumor” and “family history of
lung cancer”. Data on secondary tumor and digestive NEN
are scant, mainly collected form small series and sometimes
incomplete [32–35]. Our finding suggests that in the
pancreas some yet undefined cancer predisposition is
important for NEN development. On the same line, for lung
NEN we confirmed the “family history of cancer” as main
risk factor [14], adding “other tumor” as further risk factor.
The association of lung neuroendocrine neoplasia and other
cancer has been described, but data are limited and usually
related to the well-differentiated typical and atypical carci-
noid [36]. The concurrent cancer types are those most fre-
quently occurring in the general population, including lung
cancer (ibidem). This may well suggest the existence of
shared risk factors, including smoking [14]. Previous
malignancy has also significant negative impact in lung
carcinoid patient survival [37].
Table 1 (continued)
Characteristics Controls Cases
n % Lung NEN Pancreatic NEN
n % p valuea n % p valueb p valuec
Alcohol intensity 0.259 0.631 0.633
Never 127 51.2 37 44.0 51 51.0
≤1 drink per day 81 32.7 27 32.1 29 29.0
>1 drink per day 40 16.1 20 23.8 20 20.0
Missing 0 – 0 – 0 –
Diabetes 1 0.852 0.133 0.348
No 240 96.8 82 97.6 94 94.0
Yes 5 2.0 2 2.4 5 5.0
Missing 3 1.2 0 – 1 1.0
Diabetes 2 0.054 0.002 0.416
No 238 96.0 77 91.7 88 88.0
Yes 8 3.2 7 8.3 12 12.0
Missing 2 0.8 0 – 0 –
Other tumor <0.001 <0.001 0.845
No 238 96.0 68 81.0 79 79.0
Yes 8 3.2 16 19.0 20 20.0
Missing 2 0.8 0 – 1 1.0
Family history of tumor <0.001 0.001 0.270
No 146 58.9 27 32.1 40 40.0
Yes 102 41.1 57 67.9 60 60.0
Missing 0 – 0 – 0 –
Family history of lung cancer <0.01 <0.01 0.956
No 236 95.2 72 85.7 86 86.0
Yes 12 4.8 12 14.3 14 14.0
Missing 0 – 0 – 0 –
Text in bold means significant p value
– not computable, NEN neuroendocrine neoplasm
ap value from chi-square or t-test for comparison between lung cases and controls
bp value from chi-square or t-test for comparison between pancreas cases and controls
cp value from chi-square or t-test for comparison between pancreas cases and lung cases
dData are mean, standard deviation
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Fig. 1 Tumor type and grade
distribution among lung and
pancreas neuroendocrine
neoplasia. TC typical carcinoid,
AC atypical carcinoid, LCNEC
large cell neuroendocrine
carcinoma, SCLC small cell
lung carcinoma (WHO 2015)
[17], NET neuroendocrine
tumor, NEC neuroendocrine
carcinoma, G grade (WHO
2019) [16]
Table 2 Odds Ratios and 95% Confidence Intervals for selected covariates in lung and pancreatic neuroendocrine neoplasia
Lung NEN Pancreatic NEN All NENs
ORb 95% CI ORa 95% CI ORb 95% CI
Height 1.04 0.99–1.08 1.01 0.98–1.05 1.02 0.99–1.06
Weight 1.01 0.99–1.03 1.02 1.00–1.03 1.01 1.00–1.03
BMI
Underweight 1.00 1.00 1.00
Normal weight 1.29 0.30–5.60 0.84 0.21–3.39 1.05 0.35–3.17
Overweight 0.95 0.23–3.99 1.06 0.27–4.01 1.01 0.34–2.96
Obese 1.54 0.33–7.13 1.60 0.38–6.74 1.51 0.47–4.80
Smoking status
Never 1.00 1.00 1.00
Former 0.79 0.21–2.92 0.59 0.33–1.05 0.91 0.34–2.45
Current 0.82 0.19–3.66 0.59 0.28–1.24 0.91 0.28–2.92
Smoking intensity
Never 1.00 1.00 1.00
≤15 pack-years 1.14 0.55–2.35 0.80 0.44–1.46 0.87 0.52–1.47
>15 pack-years 1.65 0.86–3.17 0.43 0.22–1.04 0.84 0.50–1.40
Alcohol status
Never 1.00 1.00 1.00
Former 0.81 0.22–2.96 1.31 0.46–3.78 1.36 0.53–3.51
Current 0.97 0.54–1.74 0.78 0.46–1.33 0.90 0.58–1.41
Alcohol consumption
Never 1.00 1.00 1.00
≤1 drink per day 0.98 0.52–1.85 0.82 0.46–1.46 0.96 0.59–1.54
>1 drink per day 0.91 0.43–1.95 0.85 0.42–1.71 0.92 0.51–1.67
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The present series reflects the cancer-type distribution of
pancreas neuroendocrine neoplasia in the general popula-
tion (i.e., prevalent well-differentiated tumors and low
incident poorly differentiated carcinomas) [38]. Similarly,
our series of lung NEN was enriched of the well-
differentiated carcinoid groups (about 90% of the whole
cases in study), with a relatively low number of poorly
differentiated small cell lung carcinoma, a case distribution
opposite to that occurring in the general population [17].
This likely reflects both the attraction of NEN patients by
the service offered by our referral center and the low
number of small cell lung carcinoma survivors recruited for
interview along the study period.
This study has some limitations. First, the sample size of
the present series may have reduced the actual ability to
detect risk factors with low frequency. Of note, the 11
case–control studies published had a similar sample size
with only three studies well over 200 cases [24, 39, 40].
Second, the absence of biological details (namely genetics)
of investigated cancers precluded further analysis. Lastly,
the multicenter source of the present cohort may have
introduced center-specific bias.
In conclusion, the present case–control study con-
sistently identified cancer-related variables (“other cancer”,
“family history of cancer” and “family history of lung
cancer”) as major risk factors for neuroendocrine neoplasia
development in pancreas and lung. Our data support the
need for further extensive studies on risk factors for neu-
roendocrine neoplasia.
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Table 2 (continued)
Lung NEN Pancreatic NEN All NENs
ORb 95% CI ORa 95% CI ORb 95% CI
Diabetes mellitus type 1
No 1.00 1.00 1.00
Yes 0.57 0.09–3.45 2.11 0.58–7.70 1.44 0.43–4.84
Diabetes mellitus type 2
No 1.00 1.00 1.00
Yes 1.94 0.64–5.87 3.01 1.15–7.89 2.71 1.11–6.61
Other tumor
No 1.00 1.00 1.00
Yes 7.18 2.55–20.20 5.88 2.43–14.22 7.27 3.04–17.39
Family history of tumor
No 1.00 1.00 1.00
Yes 2.66 1.53–4.64 1.94 1.19–3.17 2.24 1.47–3.40
Family history of lung cancer
No 1.00 1.00 1.00
Yes 2.56 1.05–6.24 2.60 1.13–5.95 2.54 1.22–5.30
Text in bold indicates statistically significant risk factors
– not computable
aEstimates from multivariate logistic regression adjusted for age, sex and family history of cancer
bEstimates from multivariate logistic regression adjusted for age, sex, family history of cancer and smoking intensity
Endocrine
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